Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions
NTLA Stock Forecast
Intellia Therapeutics stock forecast is as follows: an average price target of $115.90 (represents a 783.38% upside from NTLA’s last price of $13.12) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
NTLA Price Target
The average price target for Intellia Therapeutics (NTLA) is $115.90 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $252.00 to $18.00. This represents a potential 783.38% upside from NTLA's last price of $13.12.
NTLA Analyst Ratings
According to 14 Wall Street analysts, Intellia Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NTLA stock is 0 'Strong Buy' (0.00%), 14 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Intellia Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Jay Olson | Oppenheimer | $60.00 | $17.16 | 249.65% | 357.32% |
| Oct 24, 2024 | Jack Allen | Robert W. Baird | $18.00 | $15.85 | 13.56% | 37.20% |
| Aug 09, 2024 | Luca Issi | RBC Capital | $54.00 | $22.38 | 141.29% | 311.59% |
| Jun 24, 2024 | Dae Gon Ha | Stifel Nicolaus | $80.00 | $25.22 | 217.21% | 509.76% |
| Jun 24, 2024 | Jack Allen | Robert W. Baird | $24.00 | $26.00 | -7.67% | 82.93% |
| May 10, 2024 | Kostas Biliouris | BMO Capital | $70.00 | $24.84 | 181.80% | 433.54% |
| Feb 01, 2023 | - | Cantor Fitzgerald | $67.00 | $42.44 | 57.87% | 410.67% |
| Jan 04, 2023 | - | Wells Fargo | $120.00 | $36.64 | 227.51% | 814.63% |
| Dec 06, 2022 | - | Credit Suisse | $88.00 | $40.03 | 119.84% | 570.73% |
| Dec 02, 2022 | - | Leerink Partners | $86.00 | $45.80 | 87.77% | 555.49% |
The latest Intellia Therapeutics stock forecast, released on Nov 11, 2024 by Jay Olson from Oppenheimer, set a price target of $60.00, which represents a 249.65% increase from the stock price at the time of the forecast ($17.16), and a 357.32% increase from NTLA last price ($13.12).
Intellia Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 6 |
| Avg Price Target | $39.00 | $39.00 | $51.00 |
| Last Closing Price | $13.12 | $13.12 | $13.12 |
| Upside/Downside | 197.26% | 197.26% | 288.72% |
In the current month, the average price target of Intellia Therapeutics stock is $39.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 197.26% increase as opposed to Intellia Therapeutics's last price of $13.12. This month's average price target is down 0.00% compared to last quarter, and down -23.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 11, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 12, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 12, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 26, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 24, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 04, 2024 | Wedbush | Neutral | Neutral | Hold |
| Jun 04, 2024 | Citigroup | Underperform | Underperform | Hold |
Intellia Therapeutics's last stock rating was published by Oppenheimer on Nov 11, 2024. The company gave NTLA a "Outperform" rating, the same as its previous rate.
Intellia Therapeutics Financial Forecast
Intellia Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.99M | $13.59M | $12.61M | $13.57M | $13.27M | $14.03M | $11.25M | $12.85M | $7.20M | $6.55M | $6.45M | $6.59M | $22.22M | $16.26M | $12.92M | $10.94M | $10.62M |
| Avg Forecast | $10.10M | $9.99M | $9.87M | $9.76M | $8.79M | $9.10M | $11.55M | $8.91M | $9.07M | $8.28M | $19.68M | $11.24M | $12.74M | $13.05M | $12.08M | $11.83M | $11.33M | $11.89M | $9.42M | $8.54M | $8.26M | $8.66M | $12.21M | $9.86M | $13.14M | $14.90M | $9.53M | $21.98M | $9.58M | $9.17M |
| High Forecast | $24.49M | $24.21M | $23.93M | $23.66M | $21.30M | $22.05M | $27.99M | $13.67M | $29.32M | $20.07M | $19.68M | $11.24M | $35.29M | $13.35M | $29.27M | $28.68M | $27.46M | $11.89M | $9.42M | $8.54M | $8.26M | $8.66M | $12.21M | $9.86M | $13.14M | $14.90M | $9.53M | $21.98M | $9.58M | $9.17M |
| Low Forecast | $3.74M | $3.69M | $3.65M | $3.61M | $3.25M | $3.36M | $4.27M | $4.56M | $2.19M | $3.06M | $19.68M | $11.24M | $4.81M | $12.75M | $4.47M | $4.38M | $4.19M | $11.89M | $9.42M | $8.54M | $8.26M | $8.66M | $12.21M | $9.86M | $13.14M | $14.90M | $9.53M | $21.98M | $9.58M | $9.17M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 9 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 1.13% | 1.07% | 1.20% | 1.12% | 1.49% | 1.32% | 1.56% | 0.83% | 0.54% | 0.65% | 0.50% | 1.49% | 1.71% | 0.59% | 1.14% | 1.16% |
Intellia Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is $12.74M, with a low forecast of $4.81M, and a high forecast of $35.29M. NTLA's average Quarter revenue forecast represents a 6.28% increase compared to the company's last Quarter revenue of $11.99M (Sep 23).
Intellia Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 9 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-122.22M | $-123.68M | $-111.86M | $-104.66M | $-95.77M | $-98.47M | $-142.07M | $-79.36M | $-69.86M | $-67.17M | $-44.61M | $-40.59M | $-26.24M | $-30.83M | $-30.27M | $-26.69M | $-22.25M |
| Avg Forecast | $-10.10M | $-9.99M | $-9.87M | $-9.76M | $-8.79M | $-9.10M | $-11.55M | $-8.91M | $-9.07M | $-8.28M | $-19.68M | $-133.90M | $-12.74M | $-13.05M | $-12.08M | $-121.73M | $-73.36M | $-11.89M | $-9.42M | $-110.66M | $-8.26M | $-8.66M | $-12.21M | $-42.59M | $-13.14M | $-14.90M | $-9.53M | $-16.65M | $-9.58M | $-9.17M |
| High Forecast | $-3.74M | $-3.69M | $-3.65M | $-3.61M | $-3.25M | $-3.36M | $-4.27M | $-4.56M | $-2.19M | $-3.06M | $-19.68M | $-107.12M | $-4.81M | $-12.75M | $-4.47M | $-97.38M | $-58.69M | $-11.89M | $-9.42M | $-88.53M | $-8.26M | $-8.66M | $-12.21M | $-34.07M | $-13.14M | $-14.90M | $-9.53M | $-13.32M | $-9.58M | $-9.17M |
| Low Forecast | $-24.49M | $-24.21M | $-23.93M | $-23.66M | $-21.30M | $-22.05M | $-27.99M | $-13.67M | $-29.32M | $-20.07M | $-19.68M | $-160.69M | $-35.29M | $-13.35M | $-29.27M | $-146.08M | $-88.04M | $-11.89M | $-9.42M | $-132.80M | $-8.26M | $-8.66M | $-12.21M | $-51.10M | $-13.14M | $-14.90M | $-9.53M | $-19.97M | $-9.58M | $-9.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.37% | 10.24% | 0.92% | 1.43% | 8.06% | 10.46% | 1.28% | 9.60% | 8.07% | 5.50% | 1.05% | 3.09% | 1.76% | 3.23% | 1.82% | 2.79% | 2.43% |
undefined analysts predict NTLA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Intellia Therapeutics's previous annual EBITDA (undefined) of $NaN.
Intellia Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 9 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-122.22M | $-123.68M | $-92.34M | $-116.73M | $-111.28M | $-99.97M | $-149.50M | $-81.24M | $-71.64M | $-68.81M | $-46.20M | $-42.19M | $-27.84M | $-32.39M | $-31.81M | $-28.28M | $-23.63M |
| Avg Forecast | $-116.52M | $-118.27M | $-121.08M | $-135.49M | $-142.60M | $-143.21M | $-138.77M | $-139.07M | $-136.49M | $-140.41M | $-122.90M | $-136.03M | $-145.29M | $-151.35M | $-133.41M | $-123.66M | $-75.10M | $-124.65M | $-126.45M | $-112.42M | $-92.03M | $-82.14M | $-61.50M | $-44.10M | $-58.43M | $-57.30M | $-67.02M | $-17.49M | $-54.58M | $-60.03M |
| High Forecast | $-21.06M | $-21.38M | $-21.89M | $-24.49M | $-25.78M | $-25.89M | $-25.09M | $-114.06M | $-88.32M | $-25.38M | $-22.22M | $-108.82M | $-99.82M | $-122.09M | $-24.12M | $-98.93M | $-60.08M | $-124.65M | $-126.45M | $-89.94M | $-92.03M | $-82.14M | $-61.50M | $-35.28M | $-58.43M | $-57.30M | $-67.02M | $-13.99M | $-54.58M | $-60.03M |
| Low Forecast | $-332.11M | $-337.11M | $-345.11M | $-386.19M | $-406.47M | $-408.20M | $-395.53M | $-152.07M | $-169.61M | $-400.21M | $-350.31M | $-163.23M | $-164.06M | $-179.60M | $-380.27M | $-148.40M | $-90.12M | $-124.65M | $-126.45M | $-134.90M | $-92.03M | $-82.14M | $-61.50M | $-52.93M | $-58.43M | $-57.30M | $-67.02M | $-20.99M | $-54.58M | $-60.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.93% | 0.75% | 1.55% | 0.89% | 0.79% | 1.33% | 0.88% | 0.87% | 1.12% | 1.05% | 0.72% | 0.49% | 0.48% | 1.82% | 0.52% | 0.39% |
Intellia Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NTLA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Intellia Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 9 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.40M | $30.65M | $27.45M | $23.63M | $22.14M | $22.13M | $22.40M | $22.11M | $18.71M | $16.68M | $13.59M | $10.76M | $10.57M | $11.53M | $11.31M | $8.98M | $8.43M |
| Avg Forecast | $17.80M | $17.60M | $17.40M | $17.20M | $15.48M | $16.03M | $20.35M | $15.70M | $15.99M | $14.59M | $34.67M | $19.81M | $22.45M | $22.99M | $21.28M | $20.85M | $19.97M | $20.94M | $16.59M | $15.05M | $14.56M | $15.26M | $21.52M | $17.37M | $23.16M | $26.26M | $16.79M | $6.22M | $16.88M | $16.15M |
| High Forecast | $43.14M | $42.65M | $42.16M | $41.68M | $37.52M | $38.85M | $49.32M | $24.08M | $51.66M | $35.36M | $34.67M | $19.81M | $62.17M | $23.52M | $51.57M | $50.52M | $48.39M | $20.94M | $16.59M | $15.05M | $14.56M | $15.26M | $21.52M | $17.37M | $23.16M | $26.26M | $16.79M | $7.47M | $16.88M | $16.15M |
| Low Forecast | $6.58M | $6.51M | $6.43M | $6.36M | $5.73M | $5.93M | $7.53M | $8.03M | $3.86M | $5.40M | $34.67M | $19.81M | $8.48M | $22.46M | $7.87M | $7.71M | $7.38M | $20.94M | $16.59M | $15.05M | $14.56M | $15.26M | $21.52M | $17.37M | $23.16M | $26.26M | $16.79M | $4.98M | $16.88M | $16.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.28% | 1.44% | 1.32% | 1.18% | 1.06% | 1.33% | 1.49% | 1.52% | 1.23% | 0.78% | 0.78% | 0.46% | 0.40% | 0.69% | 1.82% | 0.53% | 0.52% |
Intellia Therapeutics's average Quarter SG&A projection for Dec 23 is $22.45M, based on 10 Wall Street analysts, with a range of $8.48M to $62.17M. The forecast indicates a -23.63% fall compared to NTLA last annual SG&A of $29.40M (Sep 23).
Intellia Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 9 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.38 | $-1.40 | $-1.05 | $-1.44 | $-1.46 | $-1.32 | $-2.00 | $-1.09 | $-0.97 | $-1.01 | $-0.69 | $-0.69 | $-0.47 | $-0.61 | $-0.63 | $-0.60 | $-0.49 |
| Avg Forecast | $-1.15 | $-1.17 | $-1.20 | $-1.34 | $-1.41 | $-1.42 | $-1.37 | $-1.38 | $-1.35 | $-1.39 | $-1.22 | $-1.37 | $-1.44 | $-1.50 | $-1.32 | $-1.40 | $-1.38 | $-1.29 | $-1.30 | $-1.11 | $-0.95 | $-0.85 | $-0.63 | $-0.66 | $-0.60 | $-0.59 | $-0.69 | $-0.43 | $-0.56 | $-0.62 |
| High Forecast | $-0.21 | $-0.21 | $-0.22 | $-0.24 | $-0.26 | $-0.26 | $-0.25 | $-1.13 | $-0.87 | $-0.25 | $-0.22 | $-0.25 | $-0.99 | $-1.21 | $-0.24 | $-0.25 | $-0.25 | $-1.29 | $-1.30 | $-1.11 | $-0.95 | $-0.85 | $-0.63 | $-0.66 | $-0.60 | $-0.59 | $-0.69 | $-0.43 | $-0.56 | $-0.62 |
| Low Forecast | $-3.29 | $-3.34 | $-3.42 | $-3.82 | $-4.02 | $-4.04 | $-3.92 | $-1.51 | $-1.68 | $-3.96 | $-3.47 | $-3.89 | $-1.62 | $-1.78 | $-3.77 | $-3.99 | $-3.93 | $-1.29 | $-1.30 | $-1.11 | $-0.95 | $-0.85 | $-0.63 | $-0.66 | $-0.60 | $-0.59 | $-0.69 | $-0.43 | $-0.56 | $-0.62 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 1.06% | 0.75% | 1.04% | 1.14% | 1.01% | 1.80% | 1.15% | 1.15% | 1.59% | 1.05% | 1.15% | 0.80% | 0.88% | 1.46% | 1.07% | 0.79% |
According to undefined Wall Street analysts, Intellia Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NTLA previous annual EPS of $NaN (undefined).
Intellia Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $2.22 | $39.67 | 1686.94% | Hold |
| NTLA | Intellia Therapeutics | $13.12 | $115.90 | 783.38% | Buy |
| PRME | Prime Medicine | $2.99 | $17.25 | 476.92% | Buy |
| EDIT | Editas Medicine | $2.41 | $12.85 | 433.20% | Buy |
| VERV | Verve Therapeutics | $4.55 | $19.00 | 317.58% | Buy |
| SANA | Sana Bio | $2.53 | $8.00 | 216.21% | Buy |
| BEAM | Beam Therapeutics | $24.49 | $58.50 | 138.87% | Buy |
| CRSP | CRISPR Therapeutics | $47.26 | $101.46 | 114.68% | Buy |
| CRBU | Caribou Biosciences | $1.96 | $3.00 | 53.06% | Buy |
| DNA | Ginkgo Bioworks | $6.36 | $7.34 | 15.41% | Buy |
| VRTX | Vertex Pharmaceuticals | $451.23 | $403.92 | -10.48% | Buy |